What the Evidence Actually Shows About Medical Marijuana for Cancer | Research

The takeaway

A review of cannabinoid pharmaceuticals found the strongest evidence supports their use for chemotherapy-induced nausea and AIDS-related appetite loss, with more limited data for cancer pain.

Read this if you or a loved one has cancer and is considering medical marijuana for symptom relief.

Strongest evidence: chemotherapy nausea and AIDS-related appetite loss

What the researchers found

This clinical review examined evidence for three cannabinoid pharmaceuticals: dronabinol (synthetic THC), nabilone (THC analog), and nabiximols (THC/CBD spray), along with smoked marijuana.

Dronabinol had the most established evidence base, with FDA approval for chemotherapy nausea and AIDS-related anorexia. Nabilone was also well-studied for chemotherapy nausea. Nabiximols, available only through U.S. clinical trials at the time, was used in Canada and the UK for multiple sclerosis spasticity and pain.

For cancer-specific applications, evidence centered on nausea management, appetite stimulation, and pain relief, though the pain data was more limited. The review also documented adverse effects including dizziness, euphoria, sedation, and cognitive impairment.

Why it matters

This review from a leading oncology journal provided clinicians with an evidence-based perspective on cannabinoid use in cancer care, cutting through both the hype and stigma to identify where data actually supported benefit.

The numbers in context

Three FDA-related cannabinoid drugs reviewed; dronabinol FDA-approved for two indications; nabiximols available in U.S. only through clinical trials

How the study worked

Narrative review of published clinical literature on medical marijuana and cannabinoid pharmaceuticals, with emphasis on oncology-relevant indications. Published in a major oncology journal (CA: A Cancer Journal for Clinicians).

What this study cannot tell us

Narrative review without systematic search methodology. Many reviewed studies predated modern cannabis products and potencies. Did not compare cannabinoids head-to-head with newer anti-nausea medications.

How to read the evidence

Published in a top-tier oncology journal reviewing multiple levels of evidence, though it is a narrative review rather than a systematic analysis.

When this study was published

Published in 2015. The landscape of both cannabinoid research and anti-nausea medications has evolved considerably.

The bigger picture

The gap between public enthusiasm for medical marijuana in cancer and the actual clinical evidence remains significant. Established cannabinoid pharmaceuticals have clearer evidence profiles than whole-plant cannabis for specific symptoms.

Questions still open

How do cannabinoids compare to newer antiemetic drugs for chemotherapy nausea? Would whole-plant cannabis products offer advantages over isolated cannabinoid pharmaceuticals? What is the optimal role of cannabinoids in comprehensive cancer symptom management?

Common questions

Is medical marijuana proven to help with cancer?

The strongest evidence supports specific cannabinoid pharmaceuticals for chemotherapy-induced nausea and appetite loss. Evidence for pain relief is more limited, and no evidence shows cannabinoids treat cancer itself.

What are the side effects of cannabinoid medications?

Documented adverse effects include dizziness, euphoria, sedation, confusion, and cognitive impairment. These effects vary by dose and individual tolerance.

Read the original research

Medical marijuana for cancer.

CA: a cancer journal for clinicians, 65(2), 109-22

View on PubMed ↗Publisher’s paper ↗

Citation

Kramer, Joan L. (2015). Medical marijuana for cancer.. CA: a cancer journal for clinicians, 65(2), 109-22. https://doi.org/10.3322/caac.21260